Komori
Share Issuance and Disposal4598Delta-Fly Pharma,Inc.Pharmaceuticals

Notice Regarding the Large-Scale Exercise of the 11th Series of Stock Acquisition Rights (Stock Acquisition Rights with Exercise Price Adjustment Provisions)

A total of 8,200 of the 11th Series of Stock Acquisition Rights were exercised between 1 and 17 April 2026, and 820,000 shares were delivered. The number of unexercised stock acquisition rights decreased from 19,849 to 11,649.

Worth reading
66In focus
Scored from 1 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
820000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Exercise of stock acquisition rights with an exercise price adjustment clause

発行・処分する株式数820,000Shares

820,000 shares (new shares)

Intended allottee
Macquarie Bank Limited (stated as the intended allottee)
発行済株式総数

The number of stock acquisition rights exercised since the beginning of the month represented 27.33% of the total number of the 11th Series of Stock Acquisition Rights issued. The ratio of the shares delivered in this transaction to the number of shares outstanding was not disclosed.

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
¥174 on 3 April 2026, ¥170 on 6 April, ¥176 on 8 April, ¥175 on 14 April, ¥177 on 15 April, ¥180 on 16 April, and ¥181 on 17 April. Details of the adjustment provisions and the floor price: Not disclosed
Number of Stock Acquisition Rights
The total number issued is 30,000 (not calculated from the fact that 8,200 represents 27.33% of the total number issued; the documents do not expressly state the total number issued). The number unexercised as of the end of the preceding month was 19,849, and the number currently unexercised is 11,649.
Most recent equity financing
Timing 2 February 2026 / Type Issuance of the 11th Series of Stock Acquisition Rights (Stock Acquisition Rights with Provisions for Adjusting the Exercise Price) / Amount Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalExercise of stock acquisition rights with an exercise price adjustment clause
Number of shares to be issued or disposed of820,000 shares (new shares)
Intended allotteeMacquarie Bank Limited (stated as the intended allottee)
Dilution RateThe number of stock acquisition rights exercised since the beginning of the month represented 27.33% of the total number of the 11th Series of Stock Acquisition Rights issued. The ratio of the shares delivered in this transaction to the number of shares outstanding was not disclosed.
Total number of issued shares13,175,000 shares (as of the end of the month preceding the month under review) → Not disclosed
Exercise price¥174 on 3 April 2026, ¥170 on 6 April, ¥176 on 8 April, ¥175 on 14 April, ¥177 on 15 April, ¥180 on 16 April, and ¥181 on 17 April. Details of the adjustment provisions and the floor price: Not disclosed
Number of Stock Acquisition RightsThe total number issued is 30,000 (not calculated from the fact that 8,200 represents 27.33% of the total number issued; the documents do not expressly state the total number issued). The number unexercised as of the end of the preceding month was 19,849, and the number currently unexercised is 11,649.
Most recent equity financingTiming 2 February 2026 / Type Issuance of the 11th Series of Stock Acquisition Rights (Stock Acquisition Rights with Provisions for Adjusting the Exercise Price) / Amount Not disclosed
Items this document does not state (20)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To report the bulk exercise of the 11th Series of Stock Acquisition Rights during the period from 1 to 17 April 2026.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Large-Scale Exercise of the 11th Series of Stock Acquisition Rights (Stock Acquisition Rights with Exercise Price Adjustment Provisions) | Delta-Fly Pharma,Inc. (4598) timely disclosure | Komori